Zhu K, Xiong F, Bai H, Liu W
Front Pharmacol. 2025; 16:1472896.
PMID: 40046750
PMC: 11879991.
DOI: 10.3389/fphar.2025.1472896.
Ourfali M, Hirsch D, Scranton M, Jabbour T
J Pathol Transl Med. 2025; 59(1):1-10.
PMID: 39815741
PMC: 11736277.
DOI: 10.4132/jptm.2024.11.15.
Gopal P, Hu X, Robert M, Zhang X
Hepatol Commun. 2025; 9(1.
PMID: 39774070
PMC: 11717517.
DOI: 10.1097/HC9.0000000000000628.
Vasconcelos L, Grady J, Aristizabal S, Oliveira R, Urban M, Chen S
Ultrasound Med Biol. 2024; 51(1):149-158.
PMID: 39414407
PMC: 11573631.
DOI: 10.1016/j.ultrasmedbio.2024.09.018.
Rosenthal B, Schaubel D, Lewis J, Margolis D, Goldberg D, Bittermann T
Arch Dermatol Res. 2024; 316(9):641.
PMID: 39325226
PMC: 11427564.
DOI: 10.1007/s00403-024-03404-3.
Impact of Religious Affiliation on Clinical Outcomes in Liver Transplant Patients.
Prier C, Hedges M, Tolaymat L, Walker A, Haga C, Craver E
Cureus. 2024; 16(8):e66372.
PMID: 39247012
PMC: 11379409.
DOI: 10.7759/cureus.66372.
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.
Savino A, Loglio A, Neri F, Camagni S, Pasulo L, Luca M
J Clin Med. 2024; 13(13).
PMID: 38999436
PMC: 11242808.
DOI: 10.3390/jcm13133871.
The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients.
Vogel A, Roediger R, von Ahrens D, Fortune B, Schwartz J, Frager S
Life (Basel). 2024; 14(6).
PMID: 38929668
PMC: 11204519.
DOI: 10.3390/life14060685.
Hospitalizations for opportunistic infections following transplantation and associated risk factors: A national cohort study of Medicare beneficiaries.
Mezochow A, Schaubel D, Peyster E, Lewis J, Goldberg D, Bittermann T
Transpl Infect Dis. 2024; 26(4):e14317.
PMID: 38852064
PMC: 11315637.
DOI: 10.1111/tid.14317.
Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.
Mac Curtain B, OBrien L, El Sherif O, Mc Cormack A, Carolan E, Ryan J
Gastroenterol Hepatol Bed Bench. 2024; 17(1):17-27.
PMID: 38737926
PMC: 11080689.
DOI: 10.22037/ghfbb.v17i1.2899.
Relative carcinogenicity of tacrolimus mycophenolate after solid organ transplantation and its implications for liver transplant care.
Liu D, Youssef M, Grace J, Sinclair M
World J Hepatol. 2024; 16(4):650-660.
PMID: 38689747
PMC: 11056899.
DOI: 10.4254/wjh.v16.i4.650.
Primary Care Utilization, Preventative Screening, and Control of Metabolic Syndrome in Metabolic Dysfunction-Associated Steatohepatitis Liver Transplant Recipients.
Flynn S, Saxena V, Brandman D
J Prim Care Community Health. 2024; 15:21501319241247974.
PMID: 38650519
PMC: 11036922.
DOI: 10.1177/21501319241247974.
Use of machine learning models for the prognostication of liver transplantation: A systematic review.
Chongo G, Soldera J
World J Transplant. 2024; 14(1):88891.
PMID: 38576762
PMC: 10989468.
DOI: 10.5500/wjt.v14.i1.88891.
Post-Liver Transplant Metabolic Syndrome.
Choudhury A, Singh S, Desmukh A, Sahoo B, Eslam M
J Clin Exp Hepatol. 2024; 14(4):101368.
PMID: 38523736
PMC: 10960134.
DOI: 10.1016/j.jceh.2024.101368.
Variables Associated With Hyperkalemic Renal Tubular Acidosis in Solid Organ Transplant Recipients.
Mohib O, Vanderhulst J, Catalano C, Roussoulieres A, Knoop C, Lemoine A
Cureus. 2024; 16(3):e55379.
PMID: 38434606
PMC: 10908377.
DOI: 10.7759/cureus.55379.
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.
Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J
Hepatol Int. 2024; 18(2):299-383.
PMID: 38416312
DOI: 10.1007/s12072-023-10629-3.
Metabolic Disorders in Liver Transplant Recipients: The State of the Art.
Gabrielli F, Golfieri L, Nascimbeni F, Andreone P, Gitto S
J Clin Med. 2024; 13(4).
PMID: 38398327
PMC: 10889804.
DOI: 10.3390/jcm13041014.
Algorithmic Approach to Deranged Liver Functions After Transplantation.
Mishra S, Taneja S
J Clin Exp Hepatol. 2024; 14(3):101317.
PMID: 38264576
PMC: 10801315.
DOI: 10.1016/j.jceh.2023.101317.
Immune Responses to Anti-Hepatitis C Virus Antibodies during Pre-Liver Transplantation Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Recipients Associated with Post-Liver Transplantation Allograft Injury.
Lin S, Wu K, Wang C, Huang K, Hsu L, Eng H
Antibodies (Basel). 2024; 13(1).
PMID: 38247571
PMC: 10801541.
DOI: 10.3390/antib13010007.
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.
Marrone G, Leone M, Biolato M, Liguori A, Bianco G, Spoletini G
Cancers (Basel). 2023; 15(23).
PMID: 38067299
PMC: 10705300.
DOI: 10.3390/cancers15235593.
